Long-term tacrine treatment in three mild Alzheimer patients: Effects on nicotinic receptors, cerebral blood flow, glucose metabolism, EEG, and cognitive abilities

Alzheimer Disease and Associated Disorders

Volumn 12, Issue 3, 1998, Pages 228-237

  Nordberg, Agneta ^a   Amberla, Kaarina ^a   Shigeta, Masahiro ^a,d   Lundqvist, Hans ^b   Viitanen, Matti ^a   Hellström Lindahl, Ewa ^a   Johansson, Monika ^c   Andersson, Jesper ^b   Hartvig, Per ^b   Lilja, Anders ^b   Långström, Bengt ^b   Winblad, Bengt ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c PMC AB   (Sweden)

^d JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

11C nicotine; 18F FDG; AChE; Alzheimer disease; EEG; H215O; Neuropsychology; PET; Tacrine

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE; NOOTROPIC AGENT; TACRINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN BLOOD FLOW; BRAIN METABOLISM; BRAIN TOMOGRAPHY; CASE REPORT; ELECTROENCEPHALOGRAM; FEMALE; GLUCOSE METABOLISM; HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 0032439950     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002093-199809000-00017     Document Type: Article

References (59)

1. Åhlin A, Nybäck H, Junthe T, Öhman G, Nordgren I. Tetrahydroaminoacridine in Alzheimer's dementia: clinical and biochemical results of a double-blind crossover trial. Hum Psychopharmacol 1991;6:109-18.
2. Alhainen K, Partanen J, Reinikainen K, et al. Discrimination of tetrahydroaminoacridine responders by a single dose pharmaco-EEG in patients with Alzheimer's disease. Neurosci Lett 1991;127:113-6.
3. Arendt T, Brückner MK, Lange M, Bigl V. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development - a study of molecular forms. Neurochem Int 1992;21: 381-96.
4. Atack JR, Perry EK, Bonham JR, Candy JM, Perry RH. Molecular forms of acetylcholinesterase and butyrylcholinesterase in the aged human central nervous system. J Neurochem 1986;47:263-77.
5. Bassant MH, Jazat F, Lamour Y. Tetrahydroaminoacridine and physostigmine increase cerebral glucose utilization in specific cortical and subcortical regions of the rat. J Cereb Blood Flow Metab 1993;13:855-64.
6. Bassant MH, Jazat-Poindessous F, Lamour Y. Effect of metrifonate, a cholinesterase inhibitor, on local cerebral glucose utilization in young and aged rats. J Cerebr Blood Flow Metab 1996;16:1014-1025.
7. Bendat JS, Piersol AG. Analysis and measurement procedures. New York: John Wiley & Sons, 1971.
8. Buschke H, Fuld PA. Evaluation, storage, retention, and retrieval in dis-ordered memory and learning. Neurology 1974;24:1019.
9. Chotas HG, Bourne JR, Teschan PE. Heuristic technique in the quantification of the electroencephalogram in renal failure. Comp Biomed Res 1979;12:229-312.
10. Cohen MB, Fitten LJ, Lake RR, Perryman KM, Graham LS, Severin R. SPECT brain imaging in Alzheimer's disease with oral tetrahydroaminoacridine and lecithin. Clin Nucl Med 1992;17:312-5.
11. Corder EH, Jelic V, Basun H, Lannfelt L, Winblad B, Nordberg A. No difference in cerebral glucose metabolism in patients with Alzheimer disease and differing apolipoprotein E genotype. Arch Neurology 1997;54:273-7.
12. Cutler NR, Sedman AJ, Prior P, et al. Steady-state pharmacokinetics of tacrine in patients with Alzheimer's disease. Psychopharmacol Bull 1990;26:231-4.
13. Davis KL, Powchik P. Tacrine. Lancet 1995;345:625-30.
14. Ebmeier KP, Hunter R, Curran S, et al. Effect of a single dose of the acetylcholinesterase inhibitor velnacrine on recognition memory and regional cerebral blood flow in Alzheimer's disease. Psychopharmacology 1992;108:103-9.
15. Ekman L, Lindström B, Roxin P. Determination of tacrine and the 1-hydroxy metabolite in plasma using HPLC. J Chromatogr 1989;494: 397-402.
16. Ellman GL, Courtney KD, Andres V, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88-95.
17. Geaney DR Soper N, Shepstone BJ, Cowen PJ. Effect of central cholinergic stimulation on regional cerebral blood flow in Alzheimer disease. Lancet 1990;335:1484-7.
18. Giacobini E. From molecular structure to Alzheimer therapy. Jpn J Pharmacol 1997;74:225-41.
19. Gustafson L, Edvinsson L, Dahlgren N, et al. Intravenous physostigmine treatment of Alzheimer's disease evaluated by psychometric, testing, regional cerebral blood flow (rCBF) measurement, and EEG. Psychopharmacology 1987;93:31-5.
20. Hartvig P, Askmark H, Aquilonius SM, Wiklund L, Lindström B. Clinical pharmacokinetics of intravenous and oral 9-amino-1,2,3,4-tetrahydroacridine, tacrine. Eur J Clin Pharmacol 1990;38:259-63.
21. 15O. J Nucl Med 1983;24:782-9.
22. 99mTc-HMPAO SPET imaging. Br J Psychiatry 1991;158:351-7.
23. Iyo M, Namba H, Fukushi K, et al. Measurement of acetylcholinesterase by positron emission tomography in the brain of healthy controls and patients with Alzheimer's disease. Lancet 1997;239:1805-9.
24. Lawrence AD, Sahakian BJ. Alzheimer disease, attention and the cholinergic system. Alzheimer Dis Assoc Disord 1995;9(suppl 2):43-9.
25. 11C-labelled alkaloids. Chemica Scripta 1982;20:46-8.
26. 11C]Nicotine binding assessed by PET: a dual tracer model evaluated in the rhesus monkey. Alzheim Dis Assoc Discord 1998;12:238-46.
27. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-44.
28. 15O autoradiographic method and dynamic PET. J Nucl Med 1989;30:1069-78.
29. Minthon L, Gustafson L, Dalfelt G, et al. Oral tetrahydroaminoacridine treatment of Alzheimer's disease evaluated clinically and by regional cerebral blood flow and EEG. Dementia 1993;4:32-42.
30. Minthon L, Nilsson K, Edvinsson L, Wendt PE, Gustafson L. Long-term effects of tacrine on regional cerebral blood flow changes in Alzheimer's disease. Dementia 1995;6:245-51.
31. Nielsen JA, Mena EE, Williams IH, Nocerini MR, Liston D. Correlation of brain levels of 9-amino-1,2,3,4-tetrahydroacridine (THA) with neurochemical and behavioural changes. Eur J Pharmacol 1989;173:53-64.
32. Nilsson L, Adem A, Hardy J, Winblad B, Nordberg A. Do tetrahydroaminoacridine (THA) and physostigmine restore acetylcholine release in Alzheimer brains via nicotinic receptors? J Neural Transm 1987;70:357-68.
33. Nordberg A. PET imaging of nicotinic receptors in Alzheimer's disease -implication with diagnosis and drug treatment. In: Becker R, Giacobini E, eds. Alzheimer disease: from molecular biology to therapy. Boston: Birkhäuser, 1996:439-44.
34. 11C-nicotine in brain of Alzheimer patients as visualized by positron emission tomography. J Neural Transm (P-D sect) 1990;2:215-224.
35. Nordberg A, Lilja A, Lundqvist H, et al. Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimer patients as visualized by positron emission tomography. Neurobiol Aging 1992;13:747-58.
36. 11C-nicotine binding in normal and Alzheimer brains - in vivo assessment using positron emission tomography. Alzheimer Dis Assoc Disord 1995;9:21-7.
37. 3H-acetylcholine binding sites in the frontal cortex of Alzheimer brains. Neurosci Lett 1986;72:115-9.
38. Nybäck H, Nyman H, Öhman G, Nordgren I, Lindström B. Preliminary experiences and result with THA for the amelioration of symptoms of Alzheimer's disease. In: Giacobini E, Becker R, eds. Current research in Alzheimer therapy. New York: Taylor & Francis, 1988:231-6.
39. Pardo JV, Fox PT, Raichle ME. Localization of a human system for sustained attention by positron emission tomography. Nature 1991; 349:61-4.
40. Patlak CS, Blasberg JD, Fenstermacher JD. Graphical evaluation of blood to brain transfer constants from multiple tissue uptake data. J Cereb Blood Flow Metab 1983;3:1-7.
41. Perryman KM, Fitten LJ. Quantitative EEG during a double-blind trial of THA and lecithin in patients with Alzheimer's disease. J Ger Psychiat Neurol 1991;4:127-33.
42. Peruzzi P, Borredon J, Seylaz J, Lacombe P. Tacrine overcompensates for the decreased blood flow induced by basal forebrain lesion in the rat. NeuroReport 1996;8:103-8.
43. Poirier J, Delisle MC, Quirion R, et al. Apolipoprotein E4 allele as a preditcor of cholinergic deficits and treatment outcome in Alzheimer's disease. Proc Natl Acad Sci USA 1995;92:12260-4.
44. Puri SK, Hsu RS, Ho I, Lasseman HB. Single-dose safety, tolerance and pharmacokinetics of HP 029 in healthy young man: A potential Alzheimer agent. J Clin Pharmacol 1989;129:278-84.
45. Riekkinen P, Kuikka J, Soininen H, Helkala EL, Hallikainen M, Riekkinen P. Tetrahydroaminoacridine modulates technetium-99m labelled ethylene dicysteinate retention in Alzheimer's disease measured with single photon emission computered tomography imaging. Neurosci Lett 1995;195:53-6.
46. Roberts C, Mäkela P, Ford J, Truman C. Serum tacrine concentrations too low. Br J Med 1994;308:1506.
47. Rogers SL, Friedhoff LT and the Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996;7:293-303.
48. Scremin OU, Allen K, Torres C, Scremin E. Physostigmine enhances blood flow metabolism ratio in neocortex. Neuropsychopharmacol 1988;1:297-303.
49. Sherman KA. Pharmacodynamics of oral E2020 and tacrine in humans: novel approaches. In: Becker R, Giacobini E, eds. Cholinergic basis for Alzheimer therapy. Boston: Birkhäuser, 1991:321-8.
50. Smith GS, de Leon MJ, George A, et al. Topography of cross-sectional and longitudinal glucose metabolism deficits in Alzheimer's disease. Pathophysiological implications. Arch Neurol 1992;49:1142-50.
51. Storandt M, Morris JC, Rubin EH, Coben LA, Berg L. Progression of senile dementia of the Alzheimer type on a battery of psychometric tests. In: Bäckman L, ed. Memory functioning in dementia. Amsterdam: Elsevier, 1992:207-26.
52. Svensson A-L, Nordberg A. Tacrine interacts with an allosteric activator site on α4β2 nAChRs in M10 cells. NeuroReport 1996;7:2201-5.
53. Svensson AL, Warpman U, Hellström-Lundahl E, Bogdanovic N. Lannfelt I, Nordberg A. Nicotinic receptors, muscarinic receptors and choline acetyltransferase activity in the temporal cortex of Alzheimer patients with differing apolipoprotein E genotype. Neurosci Lett 1997;234:1-4.
54. Telting-Diaz M, Lunte CE. Distribution of tacrine across the blood-brain barrier in awake, freely moving rats using in vivo microdialysis sampling. Pharmaceutical Res 1993;10:44-8.
55. Tune L, Brandt J, Frost J, et al. Physostigmine in Alzheimer's disease: effects on cognition functioning, cerebral glucose metabolism analyzed by positron emission tomography and cerebral blood flow analyzed by single photon emission tomography. Acta Psychiatr Scand 1991;suppl 366:61-5.
56. Wagstaff A, McTavish D. Tacrine - a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease. Drugs Aging 1994;4:510-40.
57. Wechsler D. Manual for the Wechsler adult intelligence scale-revised. San Antonio, TX: The Psychological Corporation, 1981.
58. Wenham PR, Price WH, Blundell G. Apolipoprotein E genotyping by one-stage PCR. Lancet 1991;337:1158-9.
59. Whitehouse PJ, Martino AM, Antuono PG, et al. Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Res 1986;371:146-51.